Alnylam Pharmaceuticals (ALNY) is drawing fresh attention after being added to the Nasdaq 100, a milestone that tends to pull in index driven demand and sharpen focus on the long term RNAi story. See ...

Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...

A technical analysis of Alnylam stock, explaining the recent correction, and what investors should expect next.

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Fintel reports that on December 11, 2025, Stifel maintained coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a Buy ...

Investors in Alnylam Pharmaceuticals, Inc. ALNY need to pay close attention to the stock based on moves in the options market ...

The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, ...

Norgine, a leading European specialty pharmaceutical company, today announced an exclusive licensing agreement under which ...

Lululemon Athletica (LULU) to exit the Nasdaq 100 as part of the gauge's annual shakeup, with Seagate (STX) and five others ...

Alnylam Pharmaceuticals, Inc. ("Alnylam") (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has entered into separate, privately negotiated repurchase agreements with ...

Leerink Partners analyst Mani Foroohar reiterated a Buy rating on Intellia Therapeutics today and set a price target of $27.00.

Six companies, including Alnylam Pharmaceuticals and Seagate Technology, will join the Nasdaq 100 when the changes take effect later this month. The updates aim to keep the index aligned with the ...